Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial




COUNTER-compliant statistics provided by IRUS-UK.
Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.